Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.59 |
| ▸ | TUBB | P07437 | 3/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337638 | 1.00 | GAA (0.71) | GAACYP19A1CYP3A4TSHRNFKB1 | |
| SCHEMBL7410835 | 0.89 | GAA (0.65) | GAACYP19A1CYP3A4TSHRNFKB1 | |
| SCHEMBL9519732 | 0.87 | CYP19A1 (0.67) | GAACYP19A1CYP3A4TSHRNFKB1 | |
| Dihydroferulic Acid SCHEMBL29383405 | 0.87 | ALOX5 (0.74) | GAACYP3A4TSHRNFKB1CYP1A2 | |
| Dihydroferulic Acid SCHEMBL347918 | 0.87 | ALOX5 (0.74) | GAACYP3A4TSHRNFKB1CYP1A2 | |
| Dihydroferulic Acid SCHEMBL30210940 | 0.87 | ALOX5 (0.74) | GAACYP3A4TSHRNFKB1CYP1A2 | |
| SCHEMBL347209 | 0.86 | FFAR4 (0.61) | MEN1KMT2AALOX5OR51E2FFAR1 | |
| SCHEMBL6339281 | 0.85 | ALOX5 (0.77) | GAACYP19A1CYP3A4TSHRNFKB1 | |
| SCHEMBL28287006 | 0.85 | CYP19A1 (0.65) | GAACYP19A1CYP3A4TSHRNFKB1 | |
| SCHEMBL3209768 | 0.85 | GAA (0.60) | GAACYP19A1CYP3A4TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230201-A1 | COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSIDADE NOVA DE LISBOA (PT) | 2023-08-23 | — | — | EP | claimed |
| CN-112409974-B | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-12-21 | — | — | CN | claimed |
| CN-112409974-A | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-02-26 | — | — | CN | claimed |
| US-20040176472-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO., INC. (JP) | 2004-09-09 | — | — | US | claimed |
| US-20030199566-A1 | Phenolic acid derivatives and composition for preventing or treating blood lipid level-related diseases comprising the same | BIONUTRIGEN CO., LTD. (KR) | 2003-10-23 | — | — | US | claimed |
| US-20020133037-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | claimed |
| EP-1231215-A1 | PROCESS FOR THE PRODUCTION OF ASPARTYLDIPEPTIDE ESTER DERIVATIVES, NOVEL INTERMEDIATES THEREFOR AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2002-08-14 | — | — | EP | claimed |
| US-20250162986-A1 | Compounds and compositions for neurodegenerative diseases | UNIVERSIDADE NOV A DE LISBOA (PT) | 2025-05-22 | — | — | US | disclosed |
| EP-4482483-A1 | COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES | UNIVERSIDADE NOVA DE LISBOA (PT) | 2025-01-01 | — | — | EP | disclosed |
| CN-118742304-A | Compounds and compositions for neurodegenerative diseases | 里斯本新大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-117990868-A | Method for evaluating influence of yoghurt on flavone and phenolic acid in orange juice by adopting in-vitro model simulating gastrointestinal digestion | 上海交通大学医学院 | 2024-05-07 | — | — | CN | disclosed |
| CN-116535366-B | Thiazole compound and preparation method and application thereof | 广州医科大学 | 2023-12-05 | — | — | CN | disclosed |
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-20030009050-A1 | Crystals of aspartame derivative | AJINOMOTO CO. INC. (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1245573-A1 | ASPARTAME DERIVATIVE CRYSTALS | Ajinomoto Co., Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133037-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1231215-A1 | PROCESS FOR THE PRODUCTION OF ASPARTYLDIPEPTIDE ESTER DERIVATIVES, NOVEL INTERMEDIATES THEREFOR AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-6150412-A | SUCH AS 4-(5-HYDROXY-4-METHOXY-2-NITROPHENYL)BUTANOIC ACID; ADMINISTERING TO INHIBIT CATECHOL-O-METHYL TRANSFERASE; TREATING PARKINSON'S DISEASE OR HYPERTENSION | ORION-YHTYMA OY (FI) | 2000-11-21 | — | — | US | disclosed |
| WO-1996037456-A1 | NEW CATECHOL DERIVATIVES | Orion-Yhtymä Oy (FI) | 1996-11-28 | — | — | WO | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133037-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | DPP4, DNPEP, IAPP | GAA 882/4885CYP19A1 3026/4885CYP3A4 1255/4885 |
| US-20030199566-A1 | Phenolic acid derivatives and composition for preventing or treating blood lipid level-related diseases comprising the same | NCEH1, HMGCR, DBH | GAA 3136/4885CYP19A1 1081/4885CYP3A4 185/4885 |
| US-20250162986-A1 | Compounds and compositions for neurodegenerative diseases | CLN6, HTT, SNCA | GAA 57/4885CYP19A1 4551/4885CYP3A4 4863/4885 |
| US-20030009050-A1 | Crystals of aspartame derivative | DNPEP, TASP1, DPP4 | GAA 425/4885CYP19A1 4680/4885CYP3A4 1874/4885 |
| US-20040176472-A1 | Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof | DPP4, DNPEP, IAPP | GAA 882/4885CYP19A1 3026/4885CYP3A4 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.